Indian FDA emphasise on strengthening drug quality

Indian FDA emphasise on strengthening drug quality, safety and efficacy of drugs in India on the occasion of 12th Foundation Day of IPC

423
Medicine
Picture: Pixabay
2 min. read

Indian FDA emphasise on strengthening drug quality, safety and efficacy of drugs in India on the occasion of 12th Foundation Day of Indian Pharmacopoeia Commission (IPC) at Ghaziabad celebrated on January 1, 2020.

IPC was established as an autonomous institution under the Union health ministry on January 1, 2009.

The occasion was graced by Rajiv Wadhawan, director Drugs, Union ministry of health and Dr V G Somani, Drugs Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO).

Dr Jai Prakash, Secretary cum Scientific Director (In-Charge) apprised about various activities and achievements of IPC since its creation.

He informed that Indian Pharmacopoeia (IP) is published by the IPC on behalf of the Union health ministry in fulfillment of the requirements of the Drugs and Cosmetics (D&C) Act, 1940 and the Rules framed thereunder.

Also read: Niti Aayog has not rejected proposal to bring medical devices under CDSCO

On this occasion, he highlighted various features of Indian Pharmacopoeia (IP), National Formulary of India (NFI) and emphasized the need of its regular updation to meet essential requirements for harmonisation of analytical methods in IP with those accepted internationally keeping in view Indian scenario.

He also explained about IP reference substances and their importance as a fingerprint criteria for emphasise on strengthening drug quality.

He also touched upon NFI updation, Pharmacovigilance Programme of India (PvPI), Materiovigilance Programme of India (MvPI), training imparted to the healthcare professionals through Skill Development Programme and collaboration of IPC with various laboratories and academic institutions.

Also read: 8 notified bodies registered now under MDR 2017

He also informed that at present PvPI is having 270 ADR Monitoring Centres all over India.

Dr Wadhawan congratulated the IPC and the expert members of the scientific body for their contributions for achieving IPC mandates.

He also commended IPC for the 1st time recognition of IP in Afghanistan and also wished to extend similar recognition in African and Asian continent countries.

He further said that IPC should present its activities at different forums to enhance its visibility.

Wadhawan visited all the divisions of IPC and discussed these in depth with IPC scientists. He discussed about IP and IP reference substance, its development and distribution network all over the country.

Also read: CDSCO Mandates Licensing Authorities To Get PERs Of 19 Specified IVD Tests

He also discussed about the PvPI and suggested that more and more Adverse Drug Reaction (ADR) Monitoring Centres (AMC) should be connected with National Coordination Centre (NCC) of the Pharmacovigilance Programme of India (PvPI).

On the occasion, Dr Somani emphasise on strengthening drug quality and also said that IPC has done a great service to the society by setting the standards for drugs in the country.

He appreciated the efforts of IPC for timely publication of the IP and emphasised that IPC should develop the latest technologies in its laboratory so that challenges in quality testing in India can be addressed.

He emphasised that IPC should do the gap analysis so that the drug standards can be developed which are actually required in India. T

en system suitability impurity standards were released by DCGI and Director (Drugs) on this occasion.

Prof K K Sharma, former professor, Department of Pharmacology, University College of Medical Sciences, New Delhi appreciated the efforts of IPC for its work done quality regarding safety, efficacy of medicines and consumer reporting of ADRs in the country.

The programme ended with vote of thanks by Dr Kalaiselvan followed by round of the IPC laboratory by the dignitaries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here